EKF Diagnostics Projects Strong Growth in 2024

EKF Diagnostics Holdings (GB:EKF) has released an update.

EKF Diagnostics Holdings PLC reports a strong start to 2024 with its Q1 performance in line with expectations and a sharp 20% increase in adjusted EBITDA compared to Q1 2023. The company highlights significant growth in high margin product lines and services, such as a 156% year-on-year increase in fermentation services and a 7% rise in β-HB sales. With an improved net cash position and continued focus on profitability, EKF projects a year of significant momentum for EBITDA margins and cash generation.

For further insights into GB:EKF stock, check out TipRanks’ Stock Analysis page.